The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC).
A. Johnsson
Research Funding - Roche
J. Frodin
No relevant relationships to disclose
A. Berglund
Honoraria - Seminar presentations
H. Hagman
No relevant relationships to disclose
J. Sundberg
No relevant relationships to disclose
D. Bergstrom
Employment or Leadership Position - Roche
R. d. Christensen
Consultant or Advisory Role - Roche
Honoraria - Roche
N. Keldsen
No relevant relationships to disclose
K. G. Spindler
No relevant relationships to disclose
A. K. M. Jakobsen
Honoraria - Roche
Research Funding - Roche